Sumesh Kachroo
Overview
Explore the profile of Sumesh Kachroo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhdanava M, Burbage S, Totev T, Kachroo S, Diaz L, Godwin B, et al.
Curr Med Res Opin
. 2025 Feb;
41(2):329-338.
PMID: 39945336
Objective: To describe potential drug-drug interactions (DDIs) with oral advanced therapies among patients with ulcerative colitis (UC) and characterize clinical assessments before ozanimod initiation. Methods: Adults with UC were selected...
2.
Kershaw J, Sanon M, Kachroo S, Barlow S, Naessens D, Willey C, et al.
Crohns Colitis 360
. 2025 Jan;
7(1):otae074.
PMID: 39834357
Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn's disease (CD) patients do not achieve disease remission or continue to...
3.
Zhdanava M, Burbage S, Boonmak P, Kachroo S, Shah A, Godwin B, et al.
Clin Ther
. 2025 Jan;
47(3):204-211.
PMID: 39743427
Purpose: In ulcerative colitis (UC), anti-tumor necrosis factor (TNF) agents often are first-line biologic therapy. Switching to a biologic with a different mode of action (ustekinumab and vedolizumab) or cycling...
4.
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, et al.
Adv Ther
. 2024 Aug;
41(10):3922-3933.
PMID: 39162983
Introduction: Fistula is a common complication of Crohn's disease (CD). Treatment with biologics has been associated with fistula healing. Long-term persistence is an important factor for a chronic inflammatory process...
5.
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, et al.
Adv Ther
. 2024 Aug;
41(10):3868-3887.
PMID: 39141283
Introduction: Persistence on advanced therapies in ulcerative colitis (UC) is a useful real-world treatment performance measure. This study compared real-world persistence during the maintenance phase among advanced therapy-naïve and -experienced...
6.
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, et al.
Curr Med Res Opin
. 2024 Aug;
40(9):1555-1562.
PMID: 39104290
Objectives: To describe and compare healthcare resource utilization (HRU) among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis (UC) initiating ustekinumab or vedolizumab in the United States. Methods: Claims...
7.
Gagnon-Sanschagrin P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, et al.
J Med Econ
. 2024 Jul;
27(1):931-940.
PMID: 38965985
Aims: Suboptimal treatment indicators, including treatment switch, are common among patients with Crohn's disease (CD), but little is known about their associated healthcare resource utilization (HRU) and costs. This study...
8.
Zhdanava M, Kachroo S, Shah A, Ding Z, Lefebvre P, Zhao R, et al.
Patient Prefer Adherence
. 2024 Apr;
18:809-820.
PMID: 38617809
Purpose: To describe real-world persistence in bio-naïve and bio-experienced adults with ulcerative colitis (UC) treated with ustekinumab, a recently approved anti-interleukin 12/23 antibody, or adalimumab, an anti-TNF biologic. Methods: This...
9.
Zhdanava M, Zhao R, Manceur A, Ding Z, Boudreau J, Kachroo S, et al.
J Manag Care Spec Pharm
. 2024 Feb;
30(2):141-152.
PMID: 38308626
Background: Chronic corticosteroid use is common in ulcerative colitis (UC); however, real-world evidence of its burden to the health care system is limited. Objective: To quantify chronic corticosteroid use burden...
10.
Zhao R, Ding Z, Gupta P, Gozalo L, Bruette R, Johnson V, et al.
J Health Econ Outcomes Res
. 2023 Nov;
10(2):111-120.
PMID: 38025989
There is limited real-world evidence on treatment patterns of patients with Crohn's disease (CD) initiating biologics with an extensive follow-up period. This study describes persistence and dose titration among CD...